drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Autologous patient T cells retrovirally transduced to co-express three CARs targeting CD19, CD20, and CD22, each with 4-1BB costimulation and CD3ΞΆ signaling, to enhance activation, proliferation, persistence, and cytotoxicity against B-lineage leukemia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are retrovirally engineered to co-express three CARs specific for CD19, CD20, and CD22, each with 4-1BB costimulation and a CD3zeta signaling domain. Upon binding these B-lineage antigens on leukemic cells, CAR signaling activates the T cells, driving proliferation, persistence, and cytotoxicity (perforin/granzyme release and cytokine-mediated killing). Targeting three antigens aims to prevent antigen escape.
drug_name
TRICAR-ALL (autologous CAR T cells)
nct_id_drug_ref
NCT05010564